ALPMY News and Press, Astellas Pharma Inc. ADR From 07/02/20

Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...

Kiniksa Reports Positive Outcome from 28-Day Clinical Trial Kiniksa Pharmaceuticals Ltd. ( KNSA ) announced that it has received positive data from its COVID-19 treatment trial. This 28 day clinical outcomes data pertains to the open label treatment protocol with mavrilimumab. The compan...

TOKYO , June 8, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced results from the Phase 3 DOLOMITES study, evaluating the efficacy and safety of roxadustat compared with darbepoetin alfa for the treatment...

It is no secret that in the field of biotech, small- to mid-cap companies that develop innovative therapies for difficult-to-treat diseases (such as cancer) and a variety of rare conditions are often acquired by large-cap players for billions of dollars. Last year, the biggest ever biotech deal...

NEW YORK and TOKYO , May 29, 2020 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated ...

TOKYO , May 29, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved XTANDI ® (enzalutamide), an oral androgen receptor signaling inhibi...

NORTHBROOK, Ill. , May 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved VESIcare LS™ (solifenacin succinate) oral suspension for ...

TOKYO and SAN FRANCISCO , May 20, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno , "FibroGen") today announced the marketing authorization application (MAA) for r...

Quick Take ORIC Pharmaceuticals ( ORIC ) intends to raise $75 million in an IPO of its common stock, per an amended S-1/A registration statement . The company is advancing a pipeline of drug candidates for the treatment of prostate cancer and solid tumors. ORIC is led by extremely capab...

Deals and Financings Qiming closed its seventh China-focused US dollar fund with $1.1 billion for early stage Healthcare and TMT investments. Currently, Qiming manages nine US dollar funds and five RMB funds with $5.3 billion of assets under management. Despite the COVID-19 pandemic, Qimin...